Pharmakon Asia is one of the best pharma industry magazine asia. Pharmakon Asia is one of the leading website and magazine covering the need of global Pharmaceutical Industry . Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmakonasia.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharmakon Asia aims of providing fast and informative articles to its readers and subscribers.
Pharmakon, in philosophy and critical theory, is a composite of three meanings: remedy, poison, and scapegoat.[1] The first and second senses refer to the everyday meaning of pharmacology (and to its sub-field, toxicology), deriving from the Greek source term φάρμακον (phármakon), denoting any drug, while the third sense refers to the pharmakos ritual of human sacrifice. A further sub-sense of pharmakon as remedy which is of interest to some current authors is given by the Liddell-Scott-Jones Greek–English Lexicon as "a means of producing something
The launch of the much-awaited healthcare programme – “Ayushman Bharat” is changing the dynamics of the healthcare sector in India as a majority of the players and MNC’s are keen to participate in this programme.
The flagship programme is coined as the world’s largest government-aided that aims to benefit around 50 core citizens.
With companies like Pfizer, GlaxoSmithKline Pharma and Abbott proposing to launch a ‘second brand’ that are low-priced than the original products, this move can bring huge relief for the economically backward families.
Sources believe that by introducing these second-brands into the Ayushman health scheme would definitely be a gigantic step in eradicating illnesses from India.
If implemented, this can erase the debt trap faced by the poor families in case of medical urgencies.At a recently concluded interaction between the US India Business Council and the National Health Agency (NHA), USIBC has put forth some strategic ideas and suggestion that includes creating “policy provisions” that ultimately exempts the products from price referencing and hence lowering the costs of these drugs.
The other suggestion was to conduct screening camps to identify the patients that would help the government to prepare a steady database.
